Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
In the primary analysis using the trial product estimand, which evaluated participants who adhered to treatment, bodyweight decreased progressively in all active treatment groups over the 26-week period, without clear evidence of reaching a plateau
Chronic rejection following kidney transplantation is a complex outcome driven by both immune and non-immune factors (1)
Use within 28 days, then reconstitute next vial
Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial
10 , 2026 ,
US$ 21.45
US$ 20.60
US$ 28.86
